IDEAYA Biosciences Inc
NASDAQ:IDYA
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
28.15
47.13
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one IDYA stock under the Base Case scenario is 11.69 USD. Compared to the current market price of 29.9 USD, IDEAYA Biosciences Inc is Overvalued by 61%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
IDEAYA Biosciences Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for IDYA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
IDEAYA Biosciences Inc
Balance Sheet Decomposition
IDEAYA Biosciences Inc
Current Assets | 932.2m |
Cash & Short-Term Investments | 920m |
Receivables | 20k |
Other Current Assets | 12.2m |
Non-Current Assets | 307.7m |
Long-Term Investments | 280.1m |
PP&E | 26.6m |
Other Non-Current Assets | 911k |
Current Liabilities | 40.7m |
Accounts Payable | 12.6m |
Accrued Liabilities | 28.1m |
Non-Current Liabilities | 18.8m |
Other Non-Current Liabilities | 18.8m |
Earnings Waterfall
IDEAYA Biosciences Inc
Revenue
|
3.9m
USD
|
Operating Expenses
|
-228.7m
USD
|
Operating Income
|
-224.8m
USD
|
Other Expenses
|
46.6m
USD
|
Net Income
|
-178.1m
USD
|
Free Cash Flow Analysis
IDEAYA Biosciences Inc
USD | |
Free Cash Flow | USD |
IDYA Profitability Score
Profitability Due Diligence
IDEAYA Biosciences Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
Score
IDEAYA Biosciences Inc's profitability score is 13/100. The higher the profitability score, the more profitable the company is.
IDYA Solvency Score
Solvency Due Diligence
IDEAYA Biosciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Score
IDEAYA Biosciences Inc's solvency score is 69/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IDYA Price Targets Summary
IDEAYA Biosciences Inc
According to Wall Street analysts, the average 1-year price target for IDYA is 57.63 USD with a low forecast of 48.48 USD and a high forecast of 69.3 USD.
Dividends
Current shareholder yield for IDYA is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The company is headquartered in South San Francisco, California and currently employs 81 full-time employees. The company went IPO on 2019-05-23. The firm is focused on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead synthetic lethality product candidate, IDE397, is a clinical-stage methionine adenosyltransferase 2a (MAT2A) inhibitor for patients with solid tumors having methylthioadenosine phosphorylase (MTAP) deletions. Its clinical-stage product candidate, darovasertib (IDE196), is a protein kinase C (PKC), inhibitor that is being evaluated as a synthetic lethal combination therapy in patients having genetically defined cancers having GNAQ or GNA11 gene mutations. Its pipeline also includes preclinical research programs directed to synthetic lethality targets PARG, Pol Theta, Werner Helicase, and certain deoxyribonucleic acid (DNA) damage targets. The PARG program is for patients having tumors with a defined biomarker based on genetic mutations.
Contact
IPO
Employees
Officers
The intrinsic value of one IDYA stock under the Base Case scenario is 11.69 USD.
Compared to the current market price of 29.9 USD, IDEAYA Biosciences Inc is Overvalued by 61%.